Vera Therapeutics, Inc. (NASDAQ:VERA) Director Beth C. Seidenberg Sells 1,177 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Beth C. Seidenberg sold 1,177 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the sale, the director now directly owns 160,376 shares in the company, valued at $6,737,395.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Vera Therapeutics Trading Up 1.9 %

VERA stock opened at $42.78 on Friday. Vera Therapeutics, Inc. has a 12-month low of $9.24 and a 12-month high of $50.78. The business’s 50-day moving average is $37.47 and its 200 day moving average is $39.09. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -20.87 and a beta of 0.99.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). On average, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price target on shares of Vera Therapeutics in a report on Monday, September 16th. Finally, Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Vera Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $51.75.

Institutional Investors Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement Association of Colorado acquired a new stake in shares of Vera Therapeutics in the second quarter valued at about $135,000. Ameritas Investment Partners Inc. raised its holdings in Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after acquiring an additional 688 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Vera Therapeutics in the 2nd quarter worth approximately $163,000. Cetera Advisors LLC acquired a new position in shares of Vera Therapeutics during the 1st quarter worth approximately $235,000. Finally, Capstone Investment Advisors LLC acquired a new position in shares of Vera Therapeutics during the 1st quarter worth approximately $248,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.